SCHEMBL5659726

SCHEMBL5659726

Cc1cc(C2(c3cc(C)c(O)c(C)c3)C(=O)N(Cc3ccccc3Cl)c3ccccc32)cc(C)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.52
ALDH1A1 P00352 5/20 0.52
TSHR P16473 3/20 0.52
HTT P42858 3/20 0.52
HSD17B10 Q99714 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 2/20 0.52
ALOX15 P16050 1/20 0.52
MAPT P10636 7/20 0.50
POLB P06746 2/20 0.48
CNR1 P21554 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47
NPSR1 Q6W5P4 1/20 0.45
EDNRB P24530 1/20 0.42
EDNRA P25101 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658580 0.95 TP53 (0.48) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL5660174 0.95 CNR1 (0.57) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL5658562 0.93 CNR1 (0.47) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL5661002 0.90 TP53 (0.45) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL5658782 0.89 TP53 (0.44) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL5659557 0.89 TP53 (0.45) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL14457600 0.89 MAPT (0.44) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL5659627 0.89 TP53 (0.45) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL5661435 0.88 TP53 (0.43) TP53ALDH1A1TSHRHTTHSD17B10
SCHEMBL14457608 0.88 TP53 (0.59) TP53ALDH1A1TSHRHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US claimed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 TP53 3370/4885ALDH1A1 723/4885TSHR 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.